Abdul Rahman
1 min read
In This Article:
On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will lead early-stage research, while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR.
A healthcare professional working on a computer terminal with a patient in the background.
The collaboration complements Lilly's existing genetic hearing loss pipeline, including AK-OTOF, a Phase I/II AAV gene therapy targeting OTOF gene mutations. Early data showed hearing restoration in a trial participant within 30 days. Eli Lilly and Company (NYSE:LLY) also signed a $1.4 billion deal with Sangamo Therapeutics for CNS gene therapy in April 2025.
Industry focus on genetic hearing loss treatments is growing, with Regeneron's DB-OTO showing measurable hearing improvements in 10 of 11 pediatric patients. Rznomics, which raised $58 million in funding, sees the partnership as a step toward global biotech expansion. CEO Seong-Wook Lee emphasized the potential of precision RNA therapeutics in treating previously untreatable diseases.
While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None.
